Management Team
James Green
Chief Executive Officer
Mr. Green is the Chief Executive Officer of Vogenx and serves as Chairman of the Vogenx board of directors. James spent the early part of his career in banking where he advised on M&A and financing transactions. He then spent several years in various transaction related business development and finance roles at global pharmaceutical company GlaxoSmithKline. Prior to Vogenx, James was CEO of both public and private clinical stage drug development companies and developed an internal biotech investing platform at a pharmaceutical contract manufacturer. James holds a BBA and MBA.
William Wilkison, Ph.D.
Chief Scientific Officer
Dr. Wilkison is the Vogenx Chief Scientific Officer, Chair of the Company’s Scientific Advisory Board, and member of the Vogenx board of directors. Before joining Vogenx, Bill was a founder and senior executive at various private and public drug development companies where he was responsible for overall pipeline strategy and oversight of all research and development activities. Dr. Wilkison spent several years at GlaxoSmithKline in Worldwide Business Development and at predecessor companies studying metabolic disease where he was responsible for target and lead identification and development. Dr. Wilkison has published numerous peer-reviewed manuscripts in the metabolic disease area and is an inventor on several issued and pending patents. Dr. Wilkison holds a Ph.D. from Duke University Medical Center and did his postdoctoral work at Harvard Medical School.
Steven Delmar
Chief Financial Officer
Mr. Delmar serves as the Vogenx Chief Financial Officer and is a member of the Company’s board of directors. He has over two decades of public company CFO and executive management experience in the pharmaceutical, telecommunications, and software industries. During that time, Steve successfully led several debt and equity financings, including an IPO, and managed the execution and integration of multiple acquisitions and private equity sale transactions. Mr. Delmar earned a Bachelor of Science in Accounting from Clemson University and passed the CPA exam in Maryland.
Bentley Cheatham
Vice President of Research & Development
Dr. Cheatham is Vice President of Research and Development at Vogenx. Prior to his work in industry, he was an Assistant Professor and ran his own laboratory at the Joslin Diabetes Center at Harvard Medical School. Prior to Vogenx, Bentley held positions of increasing responsibility at multiple life sciences and drug development companies where his responsibilities ranged from developing and adapting early-stage platform technologies, to overseeing non-clinical and clinical development teams, as well as international alliance management. Dr. Cheatham established numerous NIH-funded drug discovery programs, has published numerous peer-reviewed articles in metabolic disease and is an inventor on several patents and pending patent applications. Bentley received his Ph.D. from the University of Tennessee and did his postdoctoral work at Harvard Medical School.
James Green
Chief Executive Officer
Mr. Green is the Chief Executive Officer of Vogenx and serves as Chairman of the Vogenx board of directors. Before joining Vogenx, James was CEO of Avolynt, Inc., a privately held drug development company focused on developing novel treatments for metabolic and rare disease. Prior to Avolynt, James was Chairman and CEO of Islet Sciences, Inc., a publicly traded biotech focused on developing therapeutic and diagnostic product candidates for diabetes indications, and CEO of BHV Pharma, a clinical stage pharmaceutical company focused on developing novel therapeutics for metabolic diseases. Before founding BHV, Mr. Green worked in various business development and finance roles at global pharmaceutical company GlaxoSmithKline where he was responsible for transactions related to corporate growth. Prior to GSK, Mr. Green advised on M&A, financings, and other strategic alternatives at Bank of America, Ernst & Young, and Citigroup. Mr. Green also served as a member of the Institutional Care and Use Committee at Duke University Medical Center and on the boards of Pharmacogenetics for Every Nation Initiative, Golden Helix, and Nuada Pharmaceuticals. Mr. Green earned a Bachelor of Business Administration from the University of North Florida and an MBA with a concentration in corporate finance from the Katz Graduate School of Business at The University of Pittsburgh.
William Wilkinson, Ph.D.
Chief Scientific Officer
Dr. Wilkison is the Vogenx Chief Scientific Officer, Chair of the Company’s Scientific Advisory Board, and member of the Vogenx board of directors. Before joining Vogenx, Bill was Chief Scientific Officer at Avolynt, Inc. where he was responsible for the development and approval of of SGLT2 inhibitor remogliflozin etabonate for type 2 diabetes. Prior to Avolynt, Bill was Chief Operating Officer of Islet Sciences, Inc., a publicly traded biotech focused on developing therapeutic and diagnostic product candidates for diabetes indications. Before joining Islet Sciences, Dr. Wilkison was Chief Scientific Officer at BHV Pharma, a clinical stage pharmaceutical company. Prior to founding BHV, Dr. Wilkison spent several years at GlaxoSmithKline in Worldwide Business Development. Dr. Wilkison was a founder and Chief Operating Officer at Artecel, Inc., an adipose-derived stem cell discovery, and Zen-Bio, Inc., a biotech company focused on the development and commercialization of human adipose cells. Prior to founding Zen-Bio, Dr. Wilkison spent 6 years at Glaxo/GlaxoWellcome studying metabolic disease and was responsible for target/lead identification and development. Dr. Wilkison has published numerous peer-reviewed manuscripts in the metabolic disease area and is an inventor on several issued and pending patents. Dr. Wilkison holds a Ph.D. from Duke University Medical Center and did his postdoctoral work at Harvard Medical School.
Steven Delmar
Chief Financial Officer
Mr. Delmar serves as the Vogenx Chief Financial Officer and is a member of the Company’s board of directors. Before Vogenx, Steve served as Chief Financial Officer of privately held drug developer Avolynt, Inc. and Chief Financial Officer of Islet Sciences, Inc., a publicly traded development stage biotech company. Prior to Islet Sciences, Mr. Delmar served as Director of Business Operations at Computer Sciences Corporation (CSC), Chief Financial Officer of Integrity Management Consulting, a provider of major systems acquisition and program management support services to government agencies, and Chief Financial Officer of ACE*COMM Corporation, a publicly held telecommunications company where he successfully completed multiple acquisitions and facilitated the sale of the company to a private equity investor. Mr. Delmar also spent 22 years at Microlog Corporation, a publicly held internet software and services telecommunications company, including 15 years as an executive officer, serving most recently as Chief Financial Officer. While at Microlog, Mr. Delmar successfully led the initial public offering and secondary offerings as well as multiple acquisitions. Mr. Delmar earned a Bachelor of Science in Accounting from Clemson University and passed the CPA exam in Maryland.
Bentley Cheatham
Vice President of Research & Development
Dr. Cheatham is Vice President of Research and Development at Vogenx. Prior to Vogenx, Bentley was Vice President of R&D of Avolynt, Inc., where he was instrumental in the development and approval of SGLT2 inhibitor remogliflozin etabonate, and CEO of BHV Pharma, a clinical stage pharmaceutical company focusing on development therapeutics for diabetes. Prior to BHV, Dr. Cheatham served as Vice President at Zen-Bio and was responsible for developing and adapting early stage platform technologies for commercialization, coordinating multi-site collaborative projects with academic and commercial entities, consulting with client companies to assist in their drug development and business goals, and communicating scientific results and business strategies/opportunities to clients and investment institutions. Dr. Cheatham also established numerous NIH-funded drug discovery programs. Prior to his work in industry, Dr. Cheatham was an Assistant Professor and ran his own laboratory at the Joslin Diabetes Center at Harvard Medical School. Dr. Cheatham has published numerous peer-reviewed articles in metabolic disease. Dr. Cheatham received his Ph.D. from the University of Tennessee and did his postdoctoral work at Harvard Medical School.